Real-time enrollment status for this primary immune thrombocytopenia (itp) clinical trial
Current Status
Recruiting
Checked: October 14, 2026 at 2:04 AM UTC
| NCT Number | NCT07421167 |
| Recruiting Status | Recruiting |
| Condition | Primary Immune Thrombocytopenia (ITP) |
| Phase | PHASE2 |
| Target Enrollment | 164 participants |
| Active Locations | 16 sites in the US |
| Sponsor | Novartis Pharmaceuticals |
| Last Updated on CT.gov | October 9, 2026 (5 days ago) |
As of October 14, 2026: Clinical trial NCT07421167 is currently recruiting participants. This phase2 study for primary immune thrombocytopenia (itp) is actively seeking new participants at 16 locations across the United States. The study is sponsored by Novartis Pharmaceuticals. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07421167 is actively recruiting participants as of October 14, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 16 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07421167 was last updated 5 days ago (October 9, 2026). HelloStudys verifies this status automatically.